Adjuvant effect of a Flt3 Ligand (FL) gene-transduced xenogeneic cell line in a murine colon cancer model

Journal of Surgical Research

Volumn 108, Issue 1, 2002, Pages 148-156

  Kim, Eugene M ^a   Sivanandham, Muthukumaran ^a   Stavropoulos, Christos I ^a   Wallack, Marc K ^a  

^a ST VINCENT S HOSPITAL   (United States)

Author keywords

Flt3 ligand; Gene transduction; IL 2; Immunotherapy; Xenogeneic

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; FLT3 LIGAND; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY BURDEN; CANCER CELL CULTURE; CELL ACTIVITY; CELL LINE; CELL LYSATE; CELL PROTECTION; CLINICAL PROTOCOL; COLON CANCER; CONTROLLED STUDY; CYTOLYSIS; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNIZATION; IN VIVO STUDY; INOCULATION; MALE; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STUDENT T TEST; TARGET CELL; TRANSPLANTATION; TUMOR CELL; TUMOR GROWTH; VACCINATION;

EID: 0036440255     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.2002.6540     Document Type: Article

References (61)

1. Rosnet, O., Marchetto, S., deLapeyriere, O., and Birnbaum, D. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSFIR family. Oncogene 6: 1641, 1991.
2. Matthews, W., Jordan, C. T., Wiegand, G. W., Pardoll, D., and Lemischka, I. R. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 65: 1143, 1991.
3. Lyman, S. D., James, L., Zappone, J., Sleath, P. R., Beckmann, M. P., and Bird, T. Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene. Oncogene 8: 815, 1993.
4. Lyman, S. D., James, L., Vanden Bos, T., de Vries, P., Brasel, K., Gliniak, B., Hollingsworth, L. T., Picha, K. S., McKenna, H. J., Splett, R. R., Fletcher, F. A., Maraskovsky, E., Farrah, T., Foxworthe, D., Williams, D. E., and Beckmann, M. P. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells. Cell 75: 1157, 1993.
5. Lyman, S. D., James, L., Johnson, L., Brasel, K., de Vries, P., Escobar, S. S., Downey, H., Splett, R. R., Beckmann, P., and McKenna, H. J. Cloning of the human homologue of the murine flt3 ligand: A growth factor for early hematopoietic progenitor cells. Blood 83: 2795, 1994.
6. - cells and maintains progenitor cells in vitro. Blood 87: 3563, 1996.
7. Lyman, S. D., Stocking, K., Davison, B., Fletcher, F., Johnson, L., and Escobar, S. Structural analysis of human and murine flt3 ligand genomic loci. Oncogene 11: 1165, 1995.
8. Antonysamy, M. A., and Thomson, A. W. Flt3 ligand (FL) and its influence on immune reactivity. Cytokine 12: 87, 2000.
9. Ashihara, E., Shimazaki, C., Sudo, Y., Kikuta, T., Hirai, H., Sumikuma, T., Yamagata, N., Goto, H., Inaba, T., Fujiita, N., and Nakagawa, M. Flt-3 ligand mobilizes hematopoietic primitive and committed progenitor cells into blood in mice. Eur. J. Haematol. 60: 86, 1998.
10. Morse, M. A., Nair, S., Fernandez-Casal, M., Deng, Y., St Peter, M., Williams, R., Habeika, A., Mosca, P., Clay, T., Cumming, R. I., Fisher, E., Clavien, P., Prioa, A. D., Niedzwiecki, D., Caron, D., and Lyerly, H. K. Preoperative mobilization of circulating dendritic cells by flt3 ligand administration to patients with metastatic colon cancer. J. Clin. Oncol. 18: 3883, 2000.
11. Lyman, S. D. Biologic effects and potential clinical applications of flt3 ligand. Curr. Opin. Hematol. 5: 192, 1998.
12. Sudo, Y., Shimazaki, C., Ashihara, E., Kikuta, T., Hirai, H., Sumikuma, T., Yamagata, N., Goto, H., Inaba, T., Fujita, N., and Nakagawa, M. Synergistic effect of flt-3 ligand on the granulocyte colony-stimulating factor-induced mobilization of hematopoietic stem cells and progenitor cells into blood in mice. Blood 89: 3186, 1997.
13. Molineux, G., McCrea, C., Yan, X. Q., Kerzic, P., and McNiece, I. Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood 89: 3998, 1997.
14. Borges, L., Miller, R. E., Jones, J., Ariail, K., Whitmore, J., Fanslow, W., and Lynch, D. H. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. J. Immunol. 163: 1289, 1999.
15. Ferlazzo, G., Klein, J., Paliard, X., Wei, W., and Galy, A. Dendritic cells generated from CD34(3)progenitor cells with flt3 ligand, c-kit ligand, GM-CSF, IL-4, and TNF-α are functional antigen-presenting cells resembling mature monocyte-derived dendritic cells. J Immunother. 23: 48, 2000.
16. Gregory, S. H., Sagnimeni, A. J., Zurowski, N. B., and Thomson, A. W. Flt3 ligand pretreatment promotes protective immunity to Listeria monoctyogenes. Cytokine 13: 202, 2001.
17. Kremer, I. B., Gould, M. P., Cooper, K. D., and Heinzel, F. P. Pretreatment with recombinant flt3 ligand partially protects against progressivecutaneous Leishmaniasis in susceptible Balb/c mice. Infect. Immun. 69: 673, 2001.
18. Smith, J. R., Thackray, A. M., and Bujdoso, R. Reduced herpes simplex virus type 1 latency in flt-3 ligand-treated mice is associated with enhanced numbers of natural killer and dendritic cells. Immunology 102: 352, 2001.
19. Averbook, B. J., Schuh, J. L., Papay, R., and Maliszewski, C. Antitumor effects of flt3 ligand in transplanted murine tumor models. J. Immunother. 25: 27, 2002.
20. Wang, A., Braun, S. E., Sonpavde, G., and Cornetta, K. Anti-leukemic activity of flt3 ligand in murine leukemia. Cancer Res. 60: 1895, 2000.
21. Lynch, D. H, Andreasen, A., Maraskovsky, E., Whitmore, J., Miller, R. E., and Shuh, C. L. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. 3: 625, 1997.
22. Esche, C., Subbotin, V. M., Maliszewski, C., Lotze, M. T., and Shurin, M. R. Flt3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res. 58: 380, 1998.
23. Ciavarra, R. P., Somers, K. D., Brown, R. R., Glass, W. F., Consolvo, P. J., Wright, G. L., and Schellhammer, P. F. Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostrate cancer. Cancer Res. 60: 2081, 2000.
24. Lynch, D. H. Induction of dendritic cells (DC) by flt3 ligand (FL) promotes the generation of tumor-specific immune responses in vivo. Crit. Rev. Immunol. 18: 99, 1998.
25. Peron, J., Esche, C., Subbotin, V., Maliszewski, C., Lotze, M. T., and Shurin, M. R. Flt3-ligand administration inhibits liver metastases: Role of NK cells. J. Immunol. 161: 6164, 1998.
26. Pawlowska, A. B., Hashino, S., McKenna, H., Weigel, B. J., Taylor, P. A., and Blazar, B. R. In vitro tumor-pulsed or in vivo flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice. Blood 97: 1474, 2001.
27. Fong, L., Hou, Y., Rivas, A., Benike, C., Yuen, A., Fisher, G. A., Davis, M. M., and Engleman, E. G. Altered peptide ligand vaccination with flt3 ligand expanded dendritic cells for tumor immunotherapy. PNAS 98: 8809, 2001.
28. Braun, S. E., Chen, K., Blazar, B. R., Orchard, P. J., Sledge, G., Robertson, M. J., Broxmeyer, H. E., and Cornetta, K. Flt3 ligand antitumor activity in a murine breast cancer model: A comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action. Human Gene Ther. 10: 2141, 1999.
29. Chen, K. Braun, S., Lyman, S., Fan, Y., Traycoff, C. M., Wiebke, E. A., Gaddy, J., Sledge, G., Broxmeyer, H. E., and Cornetta, K. Antitumor activity and immunotherapeutic properties of flt3-ligand in a murine breast cancer model. Cancer Res. 57: 3511, 1997.
30. Sivanandham, M., Stavropoulos, C. I., Kim, E. M., Mancke, B., and Wallack, M. K. Therapeutic effect of colon tumor cells expressing flt-3 ligand plus systemic IL-2 in mice with syngeneic colon cancer. Cancer Immunol. Immunother. 51: 63, 2002.
31. Koppenhagen, F. J., Kupcu, Z., Wallner, G., Crommelin, D. J. A., Wagner, E., Storm, G., and Kircheis, R. Sustained cytokine delivery for anticancer vaccination: Liposomes as alternative for gene-transfected tumor cells. Clin. Cancer Res. 4: 1881, 1998.
32. Hawkins, W. G., Gold, J. S., Blachere, N. E., Bowne, W. B., Hoos, A., Lewis, J. J., and Houghton, A. N. Xenogeneic DNA immunization in melanoma models for minimal residual disease. J. Surg. Res. 102: 137, 2002.
33. Iwadate, Y., Yamaura, A., Sato, Y., Sakiyama, S., and Tagawa, M. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors. Cancer Res. 61: 8769, 2001.
34. Wei, Y., Wang, Q., Zhao, X., Yang, L., Tian, L., Lu, Y., Kang, B., Lu, C., Huang, M., Lou, Y., Xiao, F., He, Q., Shu, J., Xie, X., Mao, Y., Lei, S., Luo, F., Zhou, L., Liu, C., Zhou, H., Jiang, Y., Peng, F., Yuan, L., Li, Q., Wu, Y., and Liu, J. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat. Med. 6: 1160, 2000.
35. Link, C. J., Seregina, T., Traynor, A., and Burt, R. K. Cellular suicide therapy of malignant disease. Oncologist 5: 68, 2000.
36. Knight, B. C., Souberbielle, B. E., Rizzardi, G. P., Ball, S. E., and Dalgleish, A. G. Allogeneic murine melanoma cell vaccine: A model for the development of human allogeneic cancer vaccine. Melanoma Res. 6: 299, 1996.
37. Fong, L., Brockstedt, D., Benike, C., Breen, J. K., Strang, G., Ruegg, C. L., and Engleman, E. G. Dendritic cell-based xeno-antigen vaccination for prostrate cancer immunotherapy. J. Immunol. 167: 7150, 2001.
38. Melcher, A., Todryk, S., Bateman, A., Chong, H., Lemoine, N. R., and Vile, R. G. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity. Cancer Res. 59: 2802, 1999.
39. Wei, Y., Huang, M., Yang, L., Zhao, X., Tian, L., Lu, Y., Shu, J., Lu, C., Niu, T., Kang, B., Mao, Y., Liu, F., Wen, Y., Lei, S., Luo, F., Zhou, L., Peng, F., Jiang, Y., Liu, J., Zhou, H., Wang, Q., He, Q., Xiao, F., Lou, Y., Xie, X., Li, Q., Wu, Y., Ding, Z., Hu, B., Hu, M., and Zhang, W. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. PNAS 98: 11545, 2001.
40. Sato, N., Michaelides, M. C., and Wallack, M. K. Characterization of tumorigenicity, mortality, metastasis, and splenomegaly of two cultured murine colon lines. Cancer Res. 41: 2267, 1981.
41. Corbett, T. H., Griswold, D. P., Roberts, B. J., Peckham, J. C., and Schabel, F. M. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 35: 2434, 1975.
42. Mach, N., Gillessen, S., Wilson, S. B., Sheehan, C., Mihm, M., and Dranoff, G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or flt3-ligand. Cancer Res. 60: 3239, 2000.
43. Shaw, S. G., Maung, A. A., Steptoe, R. J., Thomson, A. W., and Vujanovic, N. L. Expansion of functional NK cells in multiple tissue compartments of mice treated with flt3-ligand: Implications for anti-cancer and anti-viral therapy. J. Immunol. 161: 2817, 1998.
44. Steinman, R. M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9: 271, 1991.
45. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y. J., Pulendran, H., and Palucka, K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000: 767, 2000.
46. McKenna, H. J. Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic cells. Curr. Opin. Hematol. 8: 149, 2001.
47. Fichelson, S. The flt3/flk2 ligand: Structure, functions, and prospects. Eur. Cytokine Netw. 9: 7, 1998.
48. Marakovsky, E., Brasel, K., Teepe, M., Roux, E. R., Lyman, S. D., Shortman, K., and McKenna, H. J. Dramatic increase in the numbers of functionally mature dendritic cells in flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J. Exp. Med. 184: 1953, 1996.
49. Shurin, M. R., Pandharipande, P. P., Zorina, T. D., Haluszczak, C., Subbotin, V. M., Hunter, O., Brumfield, A., Storkus, W. J., Maraskovsky, E., and Lotze, M. T. Flt3 ligand induces the generation of functionally active dendritic cells in mice. Cell. Immunol. 179: 174, 1997.
50. Pulendran, B., Banchereau, J., Burkeholder, S., Kraus, E., Gui-net, E., Chalouni, C., Caron, D., Maliszewski, C., Davoust, J., Fay, J., and Palucka, K. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol. 165: 566, 2000.
51. Parajuli, P., Mosley, R. L., Pisarev, V., Chavez, J., Ulrich, A., Varney, M., Singh, R. K., and Talmadge, J. E. Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets. Exp. Hematol. 29: 1185, 2001.
52. Wesa, A. K., and Galy, A. Regulation of T cell cytokine production by dendritic cells generated in vitro from hematopoietic progenitor cells. Cell. Immunol. 208: 115, 2001.
53. Erard, F., Corthesy, P., Nabolz, M., Lowenthal, J. W., Zaech, P., Plaetinck, G., and MacDonald, H. R. Interleukin 2 is both necessary and sufficient for the growth and differentiation of lectin-stimulated cytolytic T lymphocyte precursors. J. Immunol. 134: 1644, 1985.
54. Bukowski, R. M., Goodman, P., Crawford, E. D., Sergi, J. S., Rodman, B. G., and Whitehead, R. P. Phase II trial of high-dose intermittent interleukin-2 in renal cell carcinoma: A Southwest Oncology Group study. J. Natl. Cancer Inst. 24: 143, 1990.
55. Parkinson, D. R., Abrams, J. S., Wiernik, P. H., Rayner, A. A., Margolin, K. A., van Echo, D. A., Snzol, M., Dutcher, J. P., Aronson, F. R., Doroshow, J. H., Arkins, M. B., and Hawkins, M. J. Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study. J. Clin. Oncol. 8: 1650, 1990.
56. McLaughlin, J. P., Schlom, J., Kantor, J. A., and Greiner, J. W. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res. 56: 2361, 1996.
57. Bronte, V., Tsung, K., Rao, J. B., Chen, P. W., Wang, M., Rosenberg, S. A., and Restifo, N. P. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154: 5282, 1995.
58. Shimizu, K., Fields, R. C., Redman, B. G., Giedlin, M., and Mule, J. J. Potentiation of immunologic responsiveness to den-dritic cell-based tumor vaccines by recombinant interleukin-2. Cancer J. Sci. Am. 6: S67, 2000.
59. Lotze, M. T., Hellerstedt, B., Stolinski, L., Tueting, T., Wilson, C., Kinzler, D., Vu, H., Rubin, J. T., Storkus, W., Tahara, H., Elder, E., and Whiteside, T. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy. Cancer J. Sci. Am 3:S109, S109, 1997.
60. Pulendran, B., Smith, J. L., Jenkins, M., Schoenborn, M., Ma-raskovsky, E., and Maliszewski, C. R. Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant. J. Exp. Med. 188: 2075, 1998.
61. Woiciechowsky, A., Regn, S., Kolb, H., and Roskrow, M., Leukemic dendritic cells generated in the presence of flt3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia. Leukemia 15: 246, 2001.